***Curriculum Vitae***

# JEFFERY P. STRUEWING

National Cancer Institute

National Institutes of Health

Building 41/D702

41 Library Dr MSC 5060

Bethesda, MD 20892-5060

Tel (301) 435-8953

Fax (301) 435-8963

js140a@nih.gov

Date & Place of Birth: April 30, 1959; Batesville, Indiana Citizenship:
United States

***Education***

1980 Queen Elizabeth College, London, England

1981 A.B. (Cum Laude) Wabash College, Crawfordsville, IN

1985 M.D. Indiana University School of Medicine, Indianapolis, IN

1988 M.S. Preventive Medicine, University of Maryland School of
Medicine, Baltimore, MD

***Board Certification and Licensure***

1990-Pres Board Certified, Public Health and General Preventive Medicine

1986-Pres State Medical License: California and Maryland

***Employment***

1988-1991 Epidemiologist, Navy Environmental and Preventive Medicine
Unit No. 5, San Diego, CA

1991-pres Medical Officer, Commissioned Corps, US Public Health Service

1991-1996 Investigator, Genetic Epidemiology Branch, National Cancer
Institute

1996 Research Fellow, Genetic Epidemiology Branch, National Cancer
Institute

1996-1998 Tenure-track Investigator, Genetic Epidemiology Branch,
National Cancer Institute

1998-2001 Tenure-track Investigator, Laboratory of Population Genetics,
National Cancer Institute

2001-pres Tenured Investigator, Laboratory of Population Genetics,
Center for Cancer Research, National Cancer Institute

2002-pres Adjunct Investigator, Clinical Genetics & Genetic Epidemiology
Branches, Division of Cancer Epidemiology and Genetics, National Cancer
Institute

***Additional Training***

1985-1986 Internship Family Practice, Ball Memorial Hospital, Muncie, IN

1986-1988 Residency General Preventive Medicine, University of Maryland,
Baltimore, MD

1991 \"Short Course in Medical and Experimental Mammalian Genetics\",
The Jackson Laboratory and Johns Hopkins University School of Medicine,
Bar Harbor, ME

1991 NIH Basic Project Officer\'s Course

1992 \"Analytic Methods in Human Genetics\", 2-credit course, Foundation
for Advanced Education in the Sciences, NIH, Bethesda, MD

2003 ½-day courses Statistical Analysis with R, Fundamentals of Unix,
NIH Center for Information Technology

2004 1 week of course in the Summer Institute in Statistical Genetics,
North Carolina State University, Raleigh, NC

***Awards***

1988 Best Student Research Presentation, University of Maryland

1990 Navy Achievement Medal

1991 Navy Commendation Medal

1995. Public Health Service Commendation Medal

1998 Sir Henry Wellcome Award from the Association of Military Surgeons
of the United States

1999 Presidential Early Career Award for Scientists and Engineers

2002. Charles Harkin Award for Research in Thyroid Cancer, Co-PI on
      intramural grant

***Professional Societies/Activities***

American Society of Human Genetics

Board of Directors, Foundation for Genetic Education and Counseling
(2000 -- present)

Steering Committee, Genetics, Genomics & Proteomics Faculty, NCI (2001
-- present)

Program Committee, Howard Hughes Medical Institute -- National
Institutes of Health Research Scholars Program (2001-2004)

User Oversight Committee, NCI Core Genotyping Facility (2002-present)

Steering Committee, NIH Intramural Program on Research on Women\'s
Health (2002-present)

Ad Hoc Scientist Reviewer, DOD/Army Congressionally Directed Medical
Research Program -- Breast Cancer Research Program (2002)

Steering Committee, Breast and Gynecologic Malignancies Faculty, NCI
(2003-present)

PDQ Cancer Genetics Editorial Board (2003-present)

Public Health Service, Full and Fair Hearing Board, July 2004

Georgetown-NIH Graduate Partnership Program Admissions Committee (2006)

Commissioned Officer, US Navy (1988-1991), US Public Health Service,
(1991-present), O6 grade

***Oral Presentations/Related Activities***

1989 31st Navy Occupational Health and Preventive Medicine Workshop,
\"Epidemiologic analysis of mass barracks evacuation\", Norfolk, VA

1989 National Society of General Internal Medicine Annual Meeting,
\"Improving colorectal cancer screening in a residents\' clinic\",
Arlington, VA

1989 Surface Force Pacific Continuing Medical Education Series, \"An
outbreak of PPD reactors on board an aircraft carrier: update of Navy
tuberculosis control program\", San Diego, CA

1990 Armed Forces Epidemiological Board, \"Navy/Marine Corps recruit
serosurvey for antibodies to measles, mumps, rubella, and varicella\",
Washington, DC

1990 32nd Navy Occupational Health and Preventive Medicine Workshop,
\"Navy/Marine Corps Recruit Serosurvey for antibodies to measles, mumps,
rubella, and varicella\", Norfolk, VA

1990 Armed Forces Epidemiological Board, Washington, DC, \"An epidemic
of pneumococcal pneumonia at Camp Pendelton, CA\", Washington, DC

1990 Armed Forces Epidemiological Board, \"Epidemic measles in San Diego
County 1990\", Washington, DC

1991 Advisory Committee on Immunization Practices (ACIP), Centers for
Disease Control, "Measles, mumps, rubella, and varicella antibody levels
among incoming military recruits\", Atlanta, GA

1991 San Diego Epidemiology Research Exchange, \"Respiratory disease due
to Streptococcus spp. among San Diego active duty military populations,
1989-1991\", San Diego, CA

1993 University of Maryland Department of Epidemiology and Preventive
Medicine, \"Genetic Epidemiology of Ovarian Cancer\", Baltimore, MD

1996 Instructor, Project LEAD, National Breast Cancer Coalition
Educational Course, Washington, DC

1996. Invited Speaker, American Association of Clinical Chemistry Annual
      Meeting, "*BRCA1* mutational analysis", Chicago, IL

1997. Plenary Speaker, National Breast Cancer Coalition Annual Meeting,
      "Update on Familial Breast Cancer", Washington, DC

1997 Invited Speaker, University of Kentucky Symposium, "Clinical
Aspects of Inherited Breast Cancer", Lexington, KY

1998. Invited Speaker, American Society of Nephrology Annual Meeting,
      "Clinical Aspects of Genetic Predisposition Testing", San Antonio,
      TX

```{=html}
<!-- -->
```
1998. Plenary Speaker, San Antonio Breast Cancer Symposium, "Familial
      breast cancer: *BRCA1* and *BRCA2*", San Antonio, TX

1998 Invited Speaker, University of California San Francisco Cancer
Center Annual Symposium, "Update on *BRCA1/2*: Cancer Risk Estimates",
San Francisco, CA

1998 Invited Speaker, National Coalition for Health Professional
Education in Genetics, "Clinical Cancer Genetics: Breast and Colon
Cancer", Washington, DC

1998. Invited Speaker, Ovarian Cancer National Alliance, "Update on
      *BRCA1/2*", Washington, DC

1998 Invited Speaker, Ohio State University Comprehensive Cancer Center,
"*BRCA1/2* and breast cancer: What are the real risks?", Colombus, OH

1999 Invited Speaker, 7^th^ Biennial Forum on Ovarian Cancer, Helene
Harris Memorial Trust, "Ovarian cancer penetrance in *BRCA1/2*",
Karolinska Institute, Stockholm, Sweden

1999 Invited Speaker, Duke University Cancer Center/Breast Cancer Spore,
"*BRCA1/2*: Risky Business", Raleigh, NC

1999. Invited Attendee, National Academy of Sciences "Frontiers of
      Science" Symposium, Irvine, CA

2000 External Reviewer, University of Alabama at Birmingham, Department
of Medicine/Division of Preventive Medicine

2001 Invited Speaker, Tumor Biology Seminar Series, Lombardi Cancer
Center, Georgetown University, "Modifiers of *BRCA1/2*", Washington, DC

2002 Invited Speaker, Pediatric Oncology Branch, NCI "The Many Functions
of *BRCA1*, Including the Possible Association with X-inactivation ",
Bethesda, MD

2003 Invited Poster Discussion Leader, Tumor Biology\\Genetics, American
Society of Clinical Oncology Annual Meeting, Chicago, IL

2003 Invited Speaker, 4^th^ Annual Conference on Gender-Specific
Medicine, Columbia University, "*BRCA1/2* and Breast Cancer", New York,
NY

2004 Invited Speaker, 4^th^ Jordan Oncology Conference/ 1^st^ King
Hussein Cancer Center - NCI Conference, King Hussein Cancer Center,
"Genetic Predisposition to Breast Cancer", Amman, Jordan

2004 Susan Teck Memorial Lecture "*BRCA1/2* and ovarian cancer", George
Washington School of Medicine, Washington, DC

***BIBLIOGRAPHY***

Book Chapters\\Invited Reviews

1\. Struewing JP. *BRCA1* in special populations. *Breast Dis* 1998;
10:71-5.

2\. Jacobs IJ, Shepherd JH, Oram DH, et al. "The penetrance of *BRCA1/*2
mutations" in Ovarian Cancer. Oxford: Oxford University Press, 2002:427.

3\. Struewing JP. Genomic approaches to identifying breast cancer
susceptibility factors. *Breast Dis* 2004;19:3-9.

Journal Articles

1\. Ash SR, Struewing JP. Clinical trials of column disc peritoneal
catheter (Lifecath, TM). *Peritoneal Dialysis Bull* 1983;3:77-80.

2\. Epstein RS, Struewing JP, Sharkness CM, Lefkowitz A, Cadigan DA,
Flynn JPG, Kessler II. Secular changes in case mix of SCI patients at
Montebello. *Maryland Med J* 1988;37:291-6.

3\. Epstein RS, Lefkowitz A, Sharkness CM, Struewing JP, Cadigan DA,
Kessler II, Flynn JPG. Predictors of rehabilitation outcome among
patients with SCI. *Maryland Med J* 1989;38:489-92.

4\. Abdel-Wahab MF, Esmat G, Narooz SI, Yosery A, Struewing JP,
Strickland GT. Sonographic studies of schoolchildren in a village
endemic for Schistosoma mansoni. *Trans Royal Soc Trop Med Hygiene*
1990;84:69-73.

5\. Struewing JP, Gray GC. An epidemic of respiratory complaints
exacerbated by mass psychogenic illness in a military recruit
population. *Am J Epidemiol* 1990;132:1120-9.

6\. Gray GC, Escamilla J, Hyams KC, Struewing JP, Kaplan EL, Tupponce
AK. Hyperendemic Streptococcus pyogenes infection despite prophylaxis
with penicillin G benzathine. *N Engl J Med* 1991;325:92-7.

7\. Gray GC, Struewing JP, Clever GC, Kulhenkamp JF. Worst California
measles epidemic in twenty-five years. *Navy Med* 1991;82(4):23-5.

8\. Struewing JP, Pape DM, Snow DA. Improving colorectal cancer
screening in a medical residents\' primary care clinic. *Am J Prev Med*
1991;7:75-81.

9\. Fujikawa J, Struewing JP, Hyams KC, Kaplan EL, Tupponce AK, Gray GC.
Oral erythromycin prophylaxis against *Streptococcus pyogenes* infection
in penicillin‑allergic military recruits: a randomized clinical trial.
*J Infect Dis* 1992;166:162‑5.

10\. Bassily S, Strickland GT, Abdel-Wahab MF, Esmat GE, Narooz S,
el-Masry NA, Constantine NT, Struewing JP. Efficacy of hepatitis B
vaccination in primary school children from a village endemic for
*Schistosoma mansoni*. *J Infect Dis* 1992;166:265-8.

11\. Hyams KC, Struewing JP, Gray GC. Seroprevalence of hepatitis A, B,
and C in a United States military recruit population. *Military Med*
1992;157:579-82.

12\. Trump, DH, Hyams KC, Cross ER, Struewing JP. Tuberculosis infection
among young adults entering the US Navy in 1990. *Arch Intern Med* 1993;
153:211-6.

13\. Amos CI, Struewing JP. Genetic epidemiology of epithelial ovarian
cancer. *Cancer* 1993;71:566-72.

14\. Gray GC, Struewing JP, Escamilla J, Hyams KC, Escamilla J, Tupponce
AK, Kaplan EL. Interpreting a single anti-streptolysin O test: a
comparison of the \"upper limit of normal\" and likelihood ratio
methods. *J Clin Epidemiol* 1993;46:1181-5.

15\. Musher DM, Groover JE, Rowland JM, Watson DA, Struewing JP, Baughn
RE, Mufson MA. Antibody to capsular polysaccharides of *Streptococcus
pneumoniae*: prevalence, persistence, and response to revaccination.
*Clin Infect Dis* 1993;17:66-73.

16\. Struewing JP, Hyams KC, Tueller JE, Gray GC. The risk of measles,
mumps, and varicella among young adults: a serosurvey of US Navy and
Marine Corps recruits. *Am J Public Health* 1993;83:1717-20.

17\. Smith SA, DiCioccio RA, Struewing JP, Easton DF, Gallion HH,
Mazoyer S, Johansson B, Steichen-Gersdorf E, Stratton M, Ford D,
Marshall G, Piver MS, Ponder BA. Localisation of the breast-ovarian
cancer susceptibility gene (BRCA1) on 17q12-21 to an interval of
[\<]{.underline} 1cM. *Genes, Chromosomes Cancer* 1994;10:71-6.

18\. Hussussian CJ^\*^, Struewing JP^\*^, Goldstein AM, Higgins PAT,
Ally DS, Sheahan MD, Clark WH Jr., Tucker MA, Dracopoli NC. Germline p16
mutations in familial melanoma. *Nat Genet* 1994;8:15-21.(^\*^
contributed equally to work)

19\. Narod SA, Ford D, Devilee P, Barkardottir RB, Lynch HT, Smith SA,
Ponder BAJ, Weber BL, Garber JE, Birch JM, Cornelis RS, Kelsell DP,
Spurr NK, Smyth E, Haites N, Sobol H, Bignon YJ, Chang-Claude J, Hamman
U, Lindblom A, Borg A, Piver MS, Gallion HH, Struewing JP, Whittemore A,
Tonin P, Goldgar DE, Easton DF, and the Breast Cancer Linkage
Consortium. An evaluation of genetic heterogeneity in 145 Breast-Ovarian
Cancer Families. *Am J Hum Genet* 1995;56:254-64.

20\. Brody LC, Abel KJ, Castilla LH, Couch FJ, McKinley DR, Yin G, Ho
PP, Merajver S, Chandrasekharappa SC, Xu J, Cole JL, Struewing JP,
Valdes JM, Collins FS, Weber BL. Construction of transcription map
surrounding the *BRCA1* locus of human chromosome 17. *Genomics*
1995;25:238-47.

21\. Struewing JP, Lerman C, Kase RG, Giambarresi TR, Tucker MA.
Anticipated uptake and impact of genetic testing in hereditary breast
and ovarian cancer families. *Cancer Epidemiol Biomarkers Prev*
1995;4:169-73.

22\. Struewing JP, Watson P, Easton DF, Ponder BAJ, Lynch HT, Tucker MA.
Prophylactic oophorectomy in inherited breast/ovarian cancer families.
*Monogr Natl Cancer Inst* 1995;17:33-5.

23\. Struewing JP, Brody LC, Erdos MR, Kase RG, Giambarresi TR, Smith
SA, Collins FS, Tucker MA. Detection of eight *BRCA1* mutations in ten
breast/ovarian cancer families, including one family with male breast
cancer. *Am J Hum Genet* 1995;57:1-7.

24\. Struewing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins
FS, Brody LC. The carrier frequency of the *BRCA1* 185delAG mutation is
approximately 1% in Ashkenazi Jewish individuals. *Nat Genet*
1995;11:198-200.

25\. Goldstein AM, Fraser MC, Struewing JP, Hussussian CJ, Zametkin DP,
Fontaine LS, Organic SM, Dracopoli NC, Clark WH Jr, Tucker MA. Increased
risk of pancreatic cancer in melanoma-prone kindreds with p16(INK4)
mutations. *New Engl J Med* 1995;333:970-4.

26\. Neuhausen SL, Mazoyer S, Friedman L, Stratton M, Offitt K, Caligo
A, Tomlinson G, Cannon-Albright L, Bishop R, Kelsel D, Solomon E, Weber
B, Couch F, Struewing J, Tonin P, Durocher F, Narod S, Skolnick MH,
Lenoir G, Serova O, Ponder B, Stoppa-Lyonnet S, Easton D, Kinc MC,
Goldgar DE. Haplotype and phenotype analysis of six recurrent *BRCA1*
mutations in 61 families: results of an international study. *Am J Hum
Genet* 1996;58:271-80.

27\. Struewing JP, Tarone RE, Brody LC, Li FP, Boice JD, Jr. BRCA1
mutations in young women with breast cancer. *Lancet* 1996; 347:1493.

28\. Smith KL, Wilson M, Hightower AW, Kelley PW, Struewing JP, Juranek
DD, McAuley JB. Prevalence of *Toxoplasma gondii* antibodies in U.S.
military recruits in 1989: comparison with data published in 1965. *Clin
Infect Dis* 1996; 23:1182-3.

29\. Tonin P, Weber B, Offit K, Couch F, Rebbeck TR, Neuhausen S, Godwin
AK, Daly M, Wagner-Costalos J, Berman D, Grana G, Fox E, Kane MF,
Kolodner RD, Krainer M, Haber DA, Struewing JP, Warner E, Rosen B,
Lerman C, Peshkin B, Norton L, Serova O, Foulkes WD, Garber JE, et al.
Frequency of recurrent *BRCA1* and *BRCA2* mutations in Ashkenazi Jewish
breast cancer families. *Nat Med* 1996; 2:1179-83.

30. Oddoux C, Struewing JP, Clayton CM, Neuhausen S, Brody LC, Kaback M,
    Haas B, Norton L, Borgen P, Jhanwar S, Goldgar D, Ostrer H, Offit K.
    The carrier frequency of the *BRCA2* 6174delT mutation among
    Ashkenazi Jewish individuals is approximately 1%. *Nat Genet* 1996;
    14:188-90.

31. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M,
    Timmerman MM, Brody LC, Tucker MA. The risk of cancer associated
    with specific mutations of *BRCA1* and *BRCA2* among Ashkenazi Jews.
    *New Engl J Med* 1997; 336:1401-8.

32\. Abbaszadegan MR, Struewing JP, Brown KM, Snider JV, Goodsaid F,
Gore-Langton R, Hughes MR. Automated detection of prevalent mutations in
*BRCA1* and *BRCA2* genes, using a fluorogenic PCR allelic
discrimination assay. *Genet Testing* 1997; 1:171-180.

33\. Emmert-Buck MR, Weiss RA, DiFranco EM, Aznavoorian, S, Linehan WM,
Vocke C, Chuaqui F, Merino MJ, Liotta LA, Zhuang Z, Struewing JP.
Allelic loss on chromosome 8p in *BRCA1* mutation positive
breast/ovarian cancers. *Breast J* 1998;4:9-12.

34\. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P,
Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD,
Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P,
Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA,
Zelada-Hedman M, et al. Genetic heterogeneity and penetrance analysis of
the *BRCA1* and *BRCA2* genes in breast cancer families. The Breast
Cancer Linkage Consortium. *Am J Hum Genet* 1998; 62:676-89.

35\. Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van
de Vijver MJ, Farid LM, Venter D, Antoniou A, Storfer-Isser A, Smyth E,
Steel CM, Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA, Ormiston
W, McManus R, Scherneck S, Ponder BAJ, Ford D, Peto J, Stoppa-Lyonnet D,
Bignon YJ, Struewing JP, Spurr NK, Bishop DT, Klijn JGM, Devilee P,
Cornelisse CJ, Lasset C, Lenoir G, Barkardottir RB, Egilsson V, Hamann
U, Chang-Claude J, Sobol H, Weber B, Stratton MR, Easton DF.
Multifactorial analysis of differences between sporadic breast cancers
and cancers involving *BRCA1* and *BRCA2* mutations. *J Natl Cancer
Inst* 1998; 90:1138-1145.

36\. Woodage T, King SM, Wacholder S, Hartge P, Struewing JP, McAdams M,
Laken SJ, Tucker MA, Brody LC. The *APC*I1307K allele and cancer risk in
a community-based study of Ashkenazi Jews. *Nat Genet* 1998; 20:62-5.

37\. Wacholder S, Hartge P, Struewing JP, Pee D, McAdams M, Brody L,
Tucker M. The kin-cohort study for estimating penetrance. *Am J
Epidemiol* 1998; 148:623-630.

38\. Thorlacius S, Struewing JP, Hartge P, Olafsdottir GH, Sigvaldason
H, Tryggvadottir L, Wacholder S, Tulinius H, Eyfjord JE.
Population-based study of risk of breast cancer in carriers of *BRCA2*
mutation. *Lancet* 1998; 352:1337-1339.

39\. Lee JS, Wacholder S, Struewing JP, McAdams M, Pee D, Brody LC,
Tucker MA, Hartge P. Survival after breast cancer in Ashkenazi Jewish
*BRCA1* and *BRCA2* mutation carriers. *J Natl Cancer Inst* 1999;
91:259-63.

40\. Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker MA. The
prevalence of common *BRCA1* and *BRCA2* mutations among Ashkenazi Jews.
*Am J Hum Genet* 1999; 64:963-970.

41\. Sherman ME, Lee JS, Burks RT, Struewing JP, Kurman RJ, Hartge P.
Histopathologic features of ovaries at increased risk for carcinoma: a
case-control analysis. *Int J Gynecol Pathol* 1999; 18:151-7.

42\. Kaufman DJ, Struewing J. Re: Effect of *BRCA1* and *BRCA2* on the
association between breast cancer risk and family history. *J Natl
Cancer Inst* 1999; 91:1250-1251.

43\. Struewing JP, Coriaty ZM, Ron E, Livoff A, Konichezky M, Cohen P,
Resnick MB, Lifzchiz-Mercerl B, Lew S, Iscovich J. Founder *BRCA1/2*
mutations among male patients with breast cancer in Israel. *Am J Hum
Genet* 1999;65:1800-1802.

44\. Lakhani SR, Gusterson BA, Jacquemier J, Sloane JP, Anderson TJ, van
de Vijver MJ, Venter D, Freeman A, Antoniou A, McGuffog L, Smyth E,
Steel CM, Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA, Ormiston
W, McManus R, Scherneck S, Ponder BAJ, Futreal PA, Peto J,
Stoppa-Lyonnet D, Bignon YJ, Struewing JP, Bishop DT, Klijn JGM, Devilee
P, Cornelisse CJ, Lasset C, Lenoir G, Barkardottir RB, Egilsson V,
Hamann U, Chang-Claude J, Sobol H, Weber B, Easton DF, Stratton MR. The
pathology of familial breast cancer: Histological features of cancers in
families not attributable to mutations in *BRCA1* or *BRCA2*. *Clin
Cancer Res* 2000; 6:782-789.

45\. Biesecker BB, Ishibe N, Hadley DW, Giambarresi TR, Kase RG, Lerman
C, Struewing JP. Psychosocial factors predicting *BRCA1/BRCA2* testing
decisions in members of hereditary breast and ovarian cancer families.
*Am J Med Genet* 2000;93:257-63.

46\. Ciotti P, Struewing JP, Mantelli M, Chompret A, Avril MF, Santi PL,
Tucker MA, Bianchi-Scarra G, Bressac-De Paillerets B, Goldstein AM. A
single genetic origin for the G101W *CDKN2A* mutation in 20
melanoma-prone families. *Am J Hum Genet* 2000; 67:311-9.

47\. Goldstein AM, Struewing JP, Chidambaram A, Fraser MC, Tucker MA.
Genotype-phenotype relationships in U.S. melanoma-prone families with
*CDKN2A* and *CDK4* mutations. *J Natl Cancer Inst* 2000; 92:1006-10.

48\. Fishman A, Dekel E, Chetrit A, Lerner-Geva L, Bar-Am A, Beck D,
Beller U, Ben-Baruch G, Piura B, Friedman E, Struewing JP, Modan B.
Patients with double primary tumors in the breast and ovary - Clinical
characteristics and *BRCA1-2* mutations status. *Gynecologic Oncol*
2000; 79:74-8.

49\. Goldstein AM, Liu L, Shennan MG, Hogg D, Tucker MA, Struewing JP. A
common founder for the V126D *CDKN2A* mutation in seven North American
melanoma-prone families. *Br J Cancer* 2001; 85:527-30.

50\. Modan B, Hartge P, Hirsh-Yechezkel G, Chetrit A, Lubin F, Beller U,
Ben-Baruch G, Fishman A, Menczer J, Ebbers SM, Tucker MA, Wacholder S,
Struewing JP, Friedman E, Piura B. Parity, oral contraceptives, and the
risk of ovarian cancer among carriers and noncarriers of a *BRCA1* or
*BRCA2* mutation. *N Engl J Med* 2001; 345:235-40.

51\. Wang WW, Spurdle AB, Kolachana P, Bove B, Modan B, Ebbers SM,
Suthers G, Tucker MA, Kaufman DJ, Doody MM, Tarone RE, Daly M, Levavi H,
Pierce H, Chetrit A, Yechezkel GH, Chenevix-Trench G, Offit K, Godwin
AK, Struewing JP. A single nucleotide polymorphism in the 5\'
untranslated region of *RAD51* and risk of cancer among *BRCA1/2*
mutation carriers. *Cancer Epidemiol Biomarkers Prev* 2001; 10:955-60.

52\. Ben David Y, Chetrit A, Hirsh-Yechezkel G, Friedman E, Beck BD,
Beller U, Ben-Baruch G, Fishman A, Levavi H, Lubin F, Menczer J, Piura
B, Struewing JP, Modan B. Effect of BRCA mutations on the length of
survival in epithelial ovarian tumors. *J Clin Oncol* 2002; 20:463-6.

53\. Pfeiffer RM, Rutter JL, Gail MH, Struewing J, Gastwirth JL.
Efficiency of DNA pooling to estimate joint allele frequencies and
measure linkage disequilibrium. *Genet Epidemiol* 2002; 22:94-102.

54\. Hartge P, Chatterjee N, Wacholder S, Brody LC, Tucker MA, Struewing
JP. Breast cancer risk in Ashkenazi *BRCA1/2* mutation carriers: Effects
of reproductive history. *Epidemiology* 2002; 13:255-261.

55\. Tucker MA, Fraser MC, Goldstein AM, Struewing JP, King MA, Crawford
JT, Chiazze EA, Zametkin DP, Fontaine LS, Clark WH, Jr. A natural
history of melanomas and dysplastic nevi. *Cancer* 2002; 94:3192-209.

56\. Zhang J, Rowe WL, Struewing JP, Buetow KH. HapScope: a software
system for automated and visual analysis of functionally annotated
haplotypes. *Nucleic Acids Res* 2002; 30:5213-21.

57\. Menczer J, Chetrit A, Barda G, Lubin F, Fishler Y, Altaras M,
Levavi H, Struewing JP, Sadetzki S, Modan B. Frequency of BRCA mutations
in primary peritoneal carcinoma in Israeli Jewish women. *Gynecol Oncol*
2003; 88:58-61.

58\. Hirsh-Yechezkel G, Chetrit A, Lubin F, Friedman E, Peretz T,
Gershoni R, Rizel S, Struewing JP, Modan B. Population attributes
affecting the prevalence of BRCA mutation carriers in epithelial ovarian
cancer cases in Israel. *Gynecol Oncol* 2003; 89:494-8.

59\. Rutter JL, Smith AM, Davila MR, Sigurdson AJ, Giusti RM, Pineda MA,
Doody MM, Tucker MA, Greene MH, Zhang J, Struewing JP. Mutational
analysis of the *BRCA1*-interacting genes *ZNF350/ZBRK1* and
*BRIP1/BACH1* among *BRCA1* and *BRCA2*-negative probands from
breast-ovarian cancer families and among early-onset breast cancer cases
and reference individuals. *Hum Mutat* 2003; 22:121-8.

60\. Rutter JL, Wacholder S, Chetrit A, Lubin F, Menczer J, Ebbers S,
Tucker MA, Struewing JP, Hartge P. Gynecologic surgeries and risk of
ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder
mutations: an Israeli population-based case-control study. *J Natl
Cancer Ins*t 2003; 95:1072-8.

61\. Rutter JL, Goldstein AM, Davila MR, Tucker MA, Struewing JP.
*CDKN2A* point mutations D153spl(c.457G\>T) and IVS2+1G\>T result in
aberrant splice products affecting both p16INK4a and p14ARF. *Oncogene*
2003; 22:4444-8.

62\. Hauptmann M, Sigurdson AJ, Chatterjee N, Rutter JL, Hill DA, Doody
MM, Struewing JP. Re: Population-based, case-control study of HER2
genetic polymorphism and breast cancer risk. *J Natl Cancer Inst* 2003;
95:1251-2.

63\. Giusti RM, Rutter JL, Duray PH, Freedman LS, Konichezky M,
Fisher-Fischbein J, Greene MH, Maslansky B, Fischbein A, Gruber SB,
Rennert G, Ronchetti RD, Hewitt SM, Struewing JP, Iscovich J. A twofold
increase in *BRCA* mutation related prostate cancer among Ashkenazi
Israelis is not associated with distinctive histopathology. *J Med
Genet* 2003;40:787-92.

64\. Kaufman DJ, Beaty TH, Struewing JP. Segregation analysis of 231
Ashkenazi Jewish families for evidence of additional breast cancer
susceptibility genes. *Cancer Epidemiol Biomarkers Prev* 2003;
12:1045-52.

65\. Rutter JL, Chatterjee N, Wacholder S, Struewing J. The HER2 I655V
polymorphism and breast cancer risk in Ashkenazim. *Epidemiology* 2003;
14:694-700.

66\. Haque KA, Pfeiffer RM, Beerman MB, Struewing JP, Chanock SJ, Bergen
AW. Performance of high-throughput DNA quantification methods. *BMC
Biotechnol* 2003; 3:20.

67\. Baccarelli A, Calista D, Minghetti P, Marinelli B, Albetti B, Tseng
T, Hedayati M, Grossman L, Landi G, Struewing JP, Landi MT. *XPD* gene
polymorphism and host characteristics in the association with cutaneous
malignant melanoma risk. *Br J Cancer* 2004; 90:497-502.

68\. Sigurdson AJ, Hauptmann M, Chatterjee N, Alexander BH, Doody MM,
Rutter JL, Struewing JP. Kin-cohort estimates for familial breast cancer
risk in relation to variants in DNA base excision repair, *BRCA1*
interacting and growth factor genes. *BMC Cancer* 2004; 4:9.

69\. Struewing JP, Hartge P, Wacholder S, Tucker MA, Greene MH. *BRCA1*
and sex ratio. *Eur J Hum Genet* 2004 ;12:663-7.

70\. Goldstein AM, Struewing JP, Fraser MC, Smith MW, Tucker MA.
Prospective risk of cancer in *CDKN2A* germline mutation carriers. *J
Med Genet* 2004;41:421-4.

71\. McInerney-Leo A, Biesecker BB, Hadley DW, Kase RG, Giambarresi TR,
Johnson E, Lerman C, Struewing JP. *BRCA1/2* testing in hereditary
breast and ovarian cancer families: Effectiveness of problem-solving
training as a counseling intervention. *Am J Med Genet* 2004;
130A:221-7.

72\. Mateus Pereira LH, Sigurdson AJ, Doody MM, Pineda MA, Alexander BH,
Greene MH, Struewing JP. *CHEK2*:1100delC and female breast cancer in
the United States. *Int J Cancer* 2004; 112:541-3.

73\. Rutter JL, Bromley CM, Goldstein AM, Elder DE, Holly EA, Guerry Dt,
Hartge P, Struewing JP, Hogg D, Halpern A, Sagebiel RW, Tucker MA.
Heterogeneity of risk for melanoma and pancreatic and digestive
malignancies. *Cancer* 2004; 101:2809-16.

74\. Wacholder S, Struewing JP, Hartge P, Greene MH, Tucker MA. Breast
cancer risks for *BRCA1/2* carriers (letter). *Science* 2004;
306:2187-91; author reply 2187-91.

75\. McInerney-Leo A, Biesecker BB, Hadley DW, Kase RG, Giambarresi TR,
Johnson E, Lerman C, Struewing JP. *BRCA1/2* testing in hereditary
breast and ovarian cancer families II: impact on relationships. *Am J
Med Genet A* 2005;133:165-9.

76\. Sigurdson AJ, Hauptmann M, Alexander BH, Doody MM, Thomas CB,
Struewing JP, Jones IM. DNA damage among thyroid cancer and multiple
cancer cases, controls, and long-lived individuals. *Mutat Res*
2005;586:173-88.

77\. Kramer JL, Velazquez IA, Chen BE, Rosenberg PS, Struewing JP,
Greene MH. Prophylactic oophorectomy reduces breast cancer penetrance
during prospective, long-term follow-up of *BRCA1* mutation carriers. *J
Clin Oncol* 2005;23:8629-8635.

78\. Ellis NA, Kirchhoff T, Mitra N, Ye TZ, Chuai S, Huang H, Nafa K,
Norton L, Neuhausen S, Gordon D, Struewing JP, Narod S, Offit K.
Localization of breast cancer susceptibility loci by genome-wide SNP
linkage disequilibrium mapping. *Genet Epidemiol* 2006;30:48-61.

79\. Struewing JP, Pineda MA, Sherman ME, Lissowska J, Brinton LA,
Peplonska B, Bardin-Mikolajczak A, Garcia-Closas M. Skewed X chromosome
inactivation and early-onset breast cancer. *J Med Genet* 2006;43:48-53.

80\. Spurdle AB, Antoniou AC, Kelemen L, Holland H, Peock S, Cook MR,
Smith PL, Greene MH, Simard J, Plourde M, Southey MC, Godwin AK, Beck J,
Miron A, Daly MB, Santella RM, Hopper JL, John EM, Andrulis IL, Durocher
F, Struewing JP, Easton DF, Chenevix-Trench G. The *AIB1* polyglutamine
repeat does not modify breast cancer risk in *BRCA1* and *BRCA2*
mutation carriers. *Cancer Epidemiol Biomarkers Prev* 2006;15:76-79.

81\. García-Closas M, Egan KM, Newcomb PA, Brinton LA, Chanock S, Welch
R, Lissowska J, Peplonska B, Szeszenia-Dąbrowska N, Zatonski W,
Bardin-Mikolajcza A, Struewing JP. Polymorphisms in DNA double strand
break repair genes and risk of breast cancer: two population-based
studies in the USA and Poland, and meta-analyses. *Hum Genet*
2006;119:376-88.

82\. Stredrick DL, Garcia-Closas M, Pineda MA, Bhatti P, Alexander BH,
Doody MM, Lissowska J, Peplonska B, Brinton LA, Chanock SJ, Struewing
JP, Sigurdson AJ. The *ATM* missense mutation Ser49Cys (c.146C\>G) and
risk of breast cancer. *Hum Mutat* 2006;27:538-44.

June 2006